4-butyrolactone has been researched along with tegafur in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Au, JL; Sadée, W | 1 |
| Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K | 1 |
| Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Yamada, Y; Yonekura, K | 1 |
| Hirata, E; Jin, HH; Komatsu, M; Mukai, K; Nagai, N; Yunokawa, M | 1 |
| Emi, Y; Fukui, Y; Kakeji, Y; Maehara, Y; Oki, E; Sumiyoshi, Y | 1 |
| Matsushima, E; Nagayama, S; Yamamiya, I; Yoshisue, K | 1 |
| Ishiguro, H; Takeuchi, M; Tanaka, S; Toi, M; Tsuji, W; Ueno, T | 1 |
1 trial(s) available for 4-butyrolactone and tegafur
| Article | Year |
|---|---|
Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.
Topics: 4-Butyrolactone; Administration, Oral; Adult; Aged; Antigens, CD34; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Count; Chemokine CCL2; Drug Combinations; Endothelial Cells; Female; Fluorouracil; Humans; Middle Aged; Neovascularization, Pathologic; Oxonic Acid; Tegafur; Thrombospondin 1; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
6 other study(ies) available for 4-butyrolactone and tegafur
| Article | Year |
|---|---|
Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone.
Topics: 4-Butyrolactone; Animals; Biotransformation; Cell-Free System; Chromatography, Gas; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Fluorouracil; Furans; Humans; Male; Metabolic Clearance Rate; Mice; Microsomes, Liver; Rabbits; Tegafur | 1980 |
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Division; Diffusion Chambers, Culture; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Hydroxybutyrates; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Tegafur; Tumor Cells, Cultured; Uracil | 1999 |
[Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice].
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Sodium Oxybate; Stomach Neoplasms; Tegafur; Tumor Cells, Cultured; Uracil | 2000 |
UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.
Topics: 4-Butyrolactone; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunohistochemistry; Middle Aged; Tegafur; Uracil; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A | 2008 |
Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer.
Topics: 4-Butyrolactone; Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Drug Combinations; Female; Humans; Hydroxybutyrates; Male; Middle Aged; Stomach Neoplasms; Tegafur; Uracil | 2007 |
Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
Topics: 4-Butyrolactone; Aldehydes; Aryl Hydrocarbon Hydroxylases; Butanols; Cytochrome P-450 CYP2A6; Cytosol; DNA, Complementary; Fluorouracil; Furans; Humans; Liver; Microsomes, Liver; Phenylhydrazines; Sodium Oxybate; Tegafur; Thymidine Phosphorylase | 2010 |